Researchers target specific protein associated with poor survival, treatment

Glioblastoma multiformeis a highly aggressive brain tumor with low survival rates, with newly diagnosed patients surviving a median of 14 months and recurrent patients surviving a median of only 3 to 9 months. New therapeutic targets and biomarkers for prognosis are urgently needed. Researchers recently reported that expression of the protein BIRC3 is associated with poor survival and recurrent disease in GBM patients; and therefore may be a good therapeutic target. (Mehr in: Cancer News — ScienceDaily)